Open an account

Bone Biologics

BBLG · NASDAQ

$0.43+$0.0195 (+4.75%)TodayMarket closed ·
Prev close $0.4105

About BBLG

Bone Biologics Corp. operates as a medical device company. The company is headquartered in Burlington, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2015-11-27. The firm is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.

Employees
2
Headquarters
Burlington, Massachusetts
Listed
Nov 27, 2015
Sector
Health Care
Industry
Biotechnology
Website
bonebiologics.com

BBLG key statistics

Market cap
1.19M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
72.39K
Volume
14.53K
Open price
$0.425
High today
$0.4427
Low today
$0.411
52 Week high
$2.60
52 Week low
$0.3788

Bone Biologics (BBLG) at a glance

Bone Biologics (BBLG) last traded at $0.43, with a market cap of 1.19M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.411 and $0.4427. The current price is 4.6% above the day's low and 2.9% below its high.

Volume so far is 14.53K shares, below the average of 72.39K shares a day.

Over the past year Bone Biologics has ranged from $0.3788 to $2.60, and now sits 2% of the way up that range.

Bone Biologics met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.43 per share against an estimate of -$0.3978.

BBLG earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 38.8% on average.

  1. Q3 FY24: reported -$14.22 per share against an estimate of -$3.67
  2. Q4 FY24: reported -$3.68 per share against an estimate of -$3.98
  3. Q1 FY25: reported -$1.92 per share against an estimate of -$2.94
  4. Q2 FY25: reported -$1.33 per share against an estimate of -$0.5916
  5. Q3 FY25: reported -$0.37 per share against an estimate of -$1.25
  6. Q4 FY25: reported -$0.14 per share against an estimate of -$0.3468
  7. Q1 FY26: reported -$0.43 per share against an estimate of -$0.5508
  8. Q2 FY26: reported -$0.43 per share against an estimate of -$0.3978

BBLG news

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Watching Bone Biologics; Zacks Small-Cap Research Gives Stock $22.20/Share Price Valuation

  • Watching Bone Biologics; Zacks Small-Cap Research Gives Stock $22.25 Price Valuation

  • Press releaseBusiness Wire

    Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook

  • Press releaseBusiness Wire

    Bone Biologics to Participate in the H.C. Wainwright Global Investment Conference

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Similar companies

Companies in the same industry as Bone Biologics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.